Barr E S & Co. Sells 100 Shares of Humana Inc. (NYSE:HUM)

Barr E S & Co. cut its position in Humana Inc. (NYSE:HUMFree Report) by 7.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,205 shares of the insurance provider’s stock after selling 100 shares during the quarter. Barr E S & Co.’s holdings in Humana were worth $585,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cibc World Market Inc. raised its position in shares of Humana by 4.0% during the first quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock worth $2,484,000 after acquiring an additional 217 shares during the last quarter. Blair William & Co. IL raised its position in shares of Humana by 0.6% during the first quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after acquiring an additional 32 shares during the last quarter. Cetera Investment Advisers raised its position in shares of Humana by 0.5% during the first quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after acquiring an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Humana by 19.0% during the first quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after acquiring an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Humana by 25.0% during the first quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock worth $12,971,000 after acquiring an additional 5,964 shares during the last quarter. 91.86% of the stock is currently owned by institutional investors.

Humana Stock Down 0.9 %

Shares of HUM stock traded down $4.25 during trading hours on Friday, reaching $467.73. The company had a trading volume of 910,018 shares, compared to its average volume of 801,681. Humana Inc. has a 12 month low of $423.29 and a 12 month high of $571.30. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.37 and a quick ratio of 1.37. The business has a fifty day simple moving average of $465.41 and a 200-day simple moving average of $488.01. The company has a market cap of $57.96 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 1.22 and a beta of 0.66.

Humana (NYSE:HUMGet Free Report) last posted its earnings results on Wednesday, August 2nd. The insurance provider reported $8.94 earnings per share for the quarter, beating analysts’ consensus estimates of $8.88 by $0.06. Humana had a return on equity of 20.70% and a net margin of 3.42%. The company had revenue of $26.75 billion for the quarter, compared to analyst estimates of $25.83 billion. During the same quarter last year, the company earned $8.67 earnings per share. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. On average, research analysts expect that Humana Inc. will post 28.25 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 29th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.76%. Humana’s dividend payout ratio is presently 13.21%.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of analyst reports. StockNews.com initiated coverage on Humana in a research report on Thursday, August 17th. They set a “buy” rating for the company. TD Cowen decreased their target price on Humana from $616.00 to $613.00 and set an “outperform” rating for the company in a research note on Tuesday, August 15th. Deutsche Bank Aktiengesellschaft raised their target price on Humana from $468.00 to $628.00 and gave the stock a “buy” rating in a research note on Monday, August 7th. Barclays decreased their target price on Humana from $620.00 to $585.00 in a research note on Monday, June 19th. Finally, Morgan Stanley decreased their target price on Humana from $637.00 to $624.00 and set an “overweight” rating for the company in a research note on Wednesday, August 30th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $592.30.

Get Our Latest Analysis on HUM

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.